Granulomatosis With Polyangiitis (GPA)
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
InflaRxIFX-1
InflaRxIFX-1 low dose
Clinical Trials (2)
Total enrollment: 77 patients across 2 trials
Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Start: Apr 2019Est. completion: Jun 202157 patients
Phase 2Completed
Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA
Start: Oct 2018Est. completion: May 202120 patients
Phase 2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space